Avance Clinical, an award-winning, mid-sized full-service global
Contract Research Organization (CRO) for biotech companies, is
pleased to announce the appointment of Jeanne Schow as Senior Vice
President, Business Development. Jeanne will be based out of the
San Francisco Bay Area.
Meet Jeanne Schow and the Avance Clinical North American team at
the next biotech event. Book a Meeting Here.
Yvonne Lungershausen, CEO of Avance Clinical, expressed her
enthusiasm about Jeanne’s appointment, highlighting the significant
expertise she brings to the team. "We are extremely pleased to have
Jeanne Schow lead our North American Business Development team.
Jeanne and the North American sales team will focus on working with
biotech clients who are seeking collaboration with Avance
Clinical’s US operations," Lungershausen stated.
"This senior appointment of an experienced industry leader to
the US operations will further support the company’s engagement
with US biotech companies seeking rapid and high-quality clinical
research solutions," Lungershausen added.
Avance Clinical’s GlobalReady drug development solution provides
innovative, accelerated clinical program pathways and quality data
accepted by all major regulatory authorities, including the FDA and
EMA. Furthermore, the company's Australian operations offer US
biotechs substantial savings of almost 45% on clinical expenditures
and facilitate rapid start-up of early-phase studies because they
do not require an IND.
Jeanne Schow brings over 25 years of experience in discovery,
clinical development, and business development roles, managing
large strategic teams. "I'm very excited to use my biotech clinical
development experience to further expand the Avance Clinical North
American operations which has more than 17 years of early to late
phase delivery experience," she said.
When asked why she chose to join Avance Clinical, Jeanne
emphasized the company’s exceptional track record of repeat
business due to customer service, responsive teams, and innovative,
quality clinical delivery across, but not limited to, key
therapeutic areas including Rare Diseases, Oncology, CNS,
Infectious Diseases, and Cell & Gene Therapies.
"As a mid-sized CRO, Avance Clinical is known for its ability to
start early in clinical development and expand to support biotech
clients through to later phase studies. We will build on this
partnership model to increase our later phase studies operated in
the US and globally.
"Avance Clinical’s US-based scientific and regulatory expertise
and collaborative project management approach aligns with the
unique challenges every study presents," she explained.
Reflecting on her career, Jeanne Schow said: "I started out with
Baxter Healthcare, working with biotech firms in the San Francisco
Bay Area, then joined Avantor, a leading scientific distributor,
followed by Acurian Patient Recruitment Services, which was
purchased by PPD during my tenure, and then joined UBC. My most
recent role was VP of Business Development at APCER Life Sciences,
which provides pharmacovigilance and regulatory services for both
clinical trials and post-approval."
"I’m proud to participate in the endeavour of discovering
treatments which prolong or improve our lives. To help one patient
find a possible new treatment through a clinical trial is one
benefit that I have both experienced as well as shared with others.
I’m thankful for the people I’ve met and look forward to meeting
more wonderful professionals as we bring Avance Clinical’s success
story to later stage biotech companies," she said.
In addition to her extensive professional experience, Jeanne
holds a Bachelor of Science degree in Industrial Technology from
California Polytechnic University in San Luis Obispo, California,
and an MBA from Pepperdine University in Malibu, California.
About Avance Clinical
| Request a ProposalAvance
Clinical is the largest premium full-service Australian, Asian and
North American CRO delivering quality clinical trials with globally
accepted data for international biotechs. The company’s clients are
biotechs completing Phase I to Phase III of their drug development
program that requires fast, agile, and adaptive solution-oriented
clinical research services.
Frost & Sullivan AwardsAvance Clinical, a
Frost & Sullivan Asia-Pacific CRO Market Leadership Award
recipient for the past four years, has been providing CRO services
in the region for more than 26 years.
Pre-clinical through to mid to late phaseAvance
Clinical offers pre-clinical consulting and regulatory services
with their experienced ClinicReady team right from pre-clinical
through to Phase III clinical services leveraging significant
Australian Government incentive rebates of up to 43.5% and rapid
start-up regulatory processes.
With experience across more than 120 indications, the CRO can
deliver world-class results and high-quality internationally
accepted data for TGA, FDA and EMA review.
TechnologyAvance Clinical uses state-of-the-art
technology and gold standard systems across all functional areas to
provide clients with the most effective processes. Medidata,
Oracle, TrialHub, Certinia, Salesforce, Zelta and Medrio are just
some of the technology partners.www.avancecro.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/e9992184-1863-4dfd-bfb6-e1a3c24810e1
Media Contact:
Avance Clinical
media@avancecro.com
Kate Thompson